Systemic Mastocytosis. Disease Overview, Pathogenesis, and Treatment

Hematology/Oncology Clinics of North America

Volumn 26, Issue 5, 2012, Pages 1117-1128

  Pardanani, Animesh ^a  

^a MAYO CLINIC   (United States)

Author keywords

KITD816V; Mast cell disease; Myeloproliferative neoplasm

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; CD2 ANTIGEN; CD34 ANTIGEN; CLADRIBINE; CROMOGLYCATE DISODIUM; HYDROXYUREA; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; MASITINIB; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MIDOSTAURIN; PREDNISONE; STEM CELL FACTOR RECEPTOR; TRYPTASE;

ABDOMINAL CRAMP; ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; BONE PAIN; CANCER PATIENT; CELL ADHESION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CHRONIC MYELOID LEUKEMIA; DEPRESSION; DIARRHEA; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; ENZYME BLOOD LEVEL; FATIGUE; FEVER; FLU LIKE SYNDROME; HEPATOSPLENOMEGALY; HISTOLOGY; HOT FLUSH; HUMAN; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LEUKOCYTOSIS; MAST CELL; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPENIA; PATHOGENESIS; PERIPHERAL EDEMA; PHOTOTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; THROMBOCYTOSIS; URTICARIA PIGMENTOSA;

HUMANS; MASTOCYTOSIS, SYSTEMIC;

EID: 84866609437     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.08.001     Document Type: Review

References (74)

1. Kirshenbaum A.S., Goff J.P., Dreskin S.C., et al. IL-3-dependent growth of basophil-like cells and mastlike cells from human bone marrow. J Immunol 1989, 142:2424-2429.
2. Kirshenbaum A.S., Kessler S.W., Goff J.P., et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991, 146:1410-1415.
3. Kirshenbaum A.S., Goff J.P., Semere T., et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999, 94:2333-2342.
4. Agis H., Willheim M., Sperr W.R., et al. Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol 1993, 151:4221-4227.
5. Rottem M., Kirshenbaum A.S., Metcalfe D.D. Early development of mast cells. Int Arch Allergy Appl Immunol 1991, 94:104-109.
6. Horny H.P., Metcalfe D.D., Bennett J.M., et al. Mastocytosis. WHO classification of tumors of hematopoietic and lymphoid tissues 2008, 54-63. International Agency for Research and Cancer (IARC), Lyon (France). 4th edition. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
7. Lim K.H., Tefferi A., Lasho T.L., et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113:5727-5736.
8. Patnaik M.M., Rindos M., Kouides P.A., et al. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007, 131:784-791.
9. Travis W.D., Li C.Y., Bergstralh E.J., et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988, 67:345-368.
10. Czarnetzki B.M., Kolde G., Schoemann A., et al. Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988, 18:45-51.
11. Jordan J.H., Walchshofer S., Jurecka W., et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001, 32:545-552.
12. Horny H.P., Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002, 127:115-117.
13. Pardanani A., Kimlinger T., Reeder T., et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004, 28:777-783.
14. Brunning R.D., McKenna R.W., Rosai J., et al. Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol 1983, 7:425-438.
15. Horny H.P., Parwaresch M.R., Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985, 16:808-814.
16. Sperr W.R., Jordan J.H., Baghestanian M., et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001, 98:2200-2209.
17. Sperr W.R., Hauswirth A.W., Valent P. Tryptase: a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma 2002, 43:2257-2261.
18. Sperr W.R., Stehberger B., Wimazal F., et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002, 43:1097-1105.
19. Samorapoompichit P., Kiener H.P., Schernthaner G.H., et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001, 98:2580-2583.
20. Schwartz L.B., Metcalfe D.D., Miller J.S., et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987, 316:1622-1626.
21. Valent P., Spanblochl E., Sperr W.R., et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992, 80:2237-2245.
22. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
23. Buttner C., Henz B.M., Welker P., et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998, 111:1227-1231.
24. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993, 92:1736-1744.
25. Sotlar K., Escribano L., Landt O., et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003, 162:737-746.
26. Beghini A., Cairoli R., Morra E., et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998, 24:262-270.
27. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999, 96:1609-1614.
28. Pullarkat V.A., Pullarkat S.T., Calverley D.C., et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000, 65:307-309.
29. Pignon J.M., Giraudier S., Duquesnoy P., et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997, 96:374-376.
30. Bodemer C., Hermine O., Palmerini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
31. Yanagihori H., Oyama N., Nakamura K., et al. c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005, 7:252-257.
32. Verzijl A., Heide R., Oranje A.P., et al. C-kit Asp-816-Val mutation analysis in patients with mastocytosis. Dermatology 2007, 214:15-20.
33. Akin C., Fumo G., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103:3222-3225.
34. Tang X., Boxer M., Drummond A., et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004, 41:e88.
35. Zappulla J.P., Dubreuil P., Desbois S., et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 2005, 202:1635-1641.
36. Gerbaulet A., Wickenhauser C., Scholten J., et al. Mast cell hyperplasia, B cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 2011, 117(6):2012-2021.
37. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
38. Tefferi A., Pardanani A., Lim K.H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23:905-911.
39. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
40. Tefferi A., Lim K.H., Abdel-Wahab O., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345.
41. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
42. Pardanani A., Lim K.H., Lasho T.L., et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010, 115:150-151.
43. Pardanani A., Lim K.H., Lasho T.L., et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114:3769-3772.
44. Zhang L.Y., Smith M.L., Schultheis B., et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006, 30:373-378.
45. Nakamura R., Chakrabarti S., Akin C., et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006, 37:353-358.
46. Casassus P., Caillat-Vigneron N., Martin A., et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002, 119:1090-1097.
47. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992, 326:619-623.
48. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998, 138:489-495.
49. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004, 28:249-257.
50. Butterfield J.H., Tefferi A., Kozuh G.F. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case. Leuk Res 2005, 29:131-134.
51. Kolde G., Sunderkotter C., Luger T.A. Treatment of urticaria pigmentosa using interferon alpha. Br J Dermatol 1995, 133:91-94.
52. Lehmann T., Beyeler C., Lammle B., et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996, 35:898-900.
53. Lehmann T., Lammle B. IFNalpha treatment in systemic mastocytosis. Ann Hematol 1999, 78:483-484.
54. Takasaki Y., Tsukasaki K., Jubashi T., et al. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha. Intern Med 1998, 37:484-488.
55. Weide R., Ehlenz K., Lorenz W., et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996, 72:41-43.
56. Lippert U., Henz B.M. Long-term effect of interferon alpha treatment in mastocytosis. Br J Dermatol 1996, 134:1164-1165. [comment].
57. Petit A., Pulik M., Gaulier A., et al. Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy. J Am Acad Dermatol 1995, 32:850-853.
58. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996, 22:501-508.
59. Brunel V., Tadrist Z., Cailleres S., et al. Presse Med 1998, 27:64. [in French].
60. Czarnetzki B.M., Algermissen B., Jeep S., et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 1994, 30:500-501.
61. Delaporte E., Pierard E., Wolthers B.G., et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995, 132:479-482.
62. Lim K.H., Pardanani A., Butterfield J.H., et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009, 84:790-794.
63. Simon J., Lortholary O., Caillat-Vigneron N., et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 2004, 52:294-299.
64. Bohm A., Sonneck K., Gleixner K.V., et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 2010, 38:744-755.
65. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006, 107:752-759.
66. Penack O., Sotlar K., Noack F., et al. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol 2005, 84:692-693.
67. Tefferi A., Li C.Y., Butterfield J.H., et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001, 344:307-309.
68. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 2003, 102:4270-4276.
69. Pardanani A., Hoffbrand A.V., Butterfield J.H., et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004, 28:127-131.
70. Zermati Y., De Sepulveda P., Feger F., et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003, 22:660-664.
71. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31:686-692.
72. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99:1741-1744.
73. Nakagomi N., Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007, 87:365-371.
74. Pardanani A. Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:401-411.